ArticleInternational journal of women's health2026
Global and Regional Impact of Pelvic Inflammatory Disease in Females Across All Age Groups (1990-2021) with Projections to 2046: Findings from the 2021 Global Burden of Disease Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pelvic inflammatory disease (PID) is a common condition among women of childbearing age, referring to a group of infectious diseases of the upper female reproductive tract, tubo-ovarian abscess, and pelvic peritonitis, primarily caused by sexually transmitted infections (STIs). Delays in diagnosis and treatment can lead to sequelae associated with PID reproductive tract infections such as tubal factor infertility, ectopic pregnancy (EP), and chronic pelvic pain. This study assessed the global burden, trends, and cross-national disparities in PID among women, with projections extending to 2046. Methods: Estimates and the corresponding 95% uncertainty intervals (UI) for the prevalence and years lived with disability (YLDs) of PID were extracted from the GBD (the Global Burden of Disease) 2021 Study. We described the epidemiology of PID at the global, regional, and national levels; analyzed trends in its burden from 1990 to 2021 on overall, local, and multidimensional scales; evaluated time trends using estimated annual percentage changes (EAPCs); and predicted changes in PID burden over the next 25 years by using Bayesian age-period-cohort (BAPC) analysis. Results: From 1990 to 2021, an increase in the age-standardized prevalence rate (ASPR) (EAPC=-0.02, 95% confidence interval (CI): -0.07 to 0.02) was observed in PID. Although our findings show an EAPC of -0.02 and stable incidence rates (ASR), the global burden continues to grow because of several factors. In 2021, the estimated number of PID cases was 1,089,544 (95% UI: 815,164 to 1,405,520), with a corresponding ASPR of 13.38 (95% UI: 10.02 to 17.28) per 100,000 population. The burden of PID varied widely across countries, with the highest ASR for prevalence and YLDs recorded in Guinea. Our predictions indicate that the prevalence and YLDs of PID will continue to rise over the next 25 years. Conclusion: PID remains a major global women's public health concern, with its burden rising from 1990 to 2021. This study highlights the persistent challenges in managing PID, and its unequal distribution, offering insights for more effective resource allocation and age-inclusive care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.